Cheraw Chronicle

Complete News World

Biocartis launches test that detects influenza and RSV in addition to coronavirus |  interior

Biocartis launches test that detects influenza and RSV in addition to coronavirus | interior

Biocartis in Mechelen has launched a test that, in addition to SARS-CoV-2 – the coronavirus – also detects influenza and RSV respiratory infection. The company reports it.

The Idylla SARS-CoV-2/Flu/RSV Panel is a fully automated test that detects SARS-CoV-2, influenza, and RSV nucleic acids in people who, according to their healthcare provider, may have a respiratory infection. The result is available in about 90 minutes.

“We are taking an important next step in strengthening the list of infectious disease testing by upgrading the Idylla SARS-CoV-2 Test5 (CE-IVD) to a panel that now includes influenza A/B and RSV,” CEO Hermann Verelst said. Press release. “In anticipation of the postponed influenza season, this committee is well positioned to guide healthcare providers through this complex landscape of respiratory infections in 2022.”


Biocartis, who specializes in biomolecular diagnostics, also says he’s had a good six months. 189 new pocket labs were installed, automated systems made molecular testing easier and cheaper, and nearly twice as many cartridges (+96 percent) were sold for these pocket labs than last year. Oncology tests have also been very successful, as have infectious disease tests. The contribution of infectious diseases can be compared to the second quarter of 2020 “against the backdrop of declining global Covid-19 testing volumes”. The turnover increased by 31 percent to more than 23 million euros.

The company is also providing an update after a heavy fire at a storage facility in Mechelen on July 30. To secure customer supplies as much as possible, the company refocused more staff and resources on its unaffected cartridge production line. In addition, additional reagents were ordered from many suppliers to replenish products lost during a fire, thus reducing production delays. Finally, oncology testing and the partner project were prioritized, reducing SARS-CoV-2 test volumes.

See also  "Wrinkles in the nose": problems with the Boeing 787 Dream again ...

Through these efforts, Biocartis can confirm cartridge volume growth of 40 percent, provided reagents are available on time. The second line affected by the fire will be able to restart by the second half of September, according to CEO Hermann Verelst.

Read also.

The Delta variant is implementing new strategies around the world: ‘We have to learn to live with the virus’ (+)